<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Brain metastases in non-small cell lung cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Brain metastases in non-small cell lung cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Brain metastases in non-small cell lung cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Benjamin Solomon, MBBS, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rogerio C Lilenbaum, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven E Schild, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1800417975"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Brain metastases are a common complication in a wide range of cancers, but they are particularly common among patients with lung cancer. Approximately 10 percent of newly diagnosed patients with advanced non-small cell lung cancer (NSCLC) have brain metastases. Of patients with brain metastases, lung cancer is the primary tumor in 40 to 50 percent of cases [<a href="#rid1">1,2</a>].</p><p>Though there are well-established management approaches for brain metastases, with local therapies as the cornerstone, treatment options for patients with advanced NSCLC and brain metastases are evolving for several reasons. First, many patients with advanced NSCLC are living several years, allowing more time for brain metastases to develop as well as for adverse effects of prior therapies for brain metastases to emerge. Second, patients with more common driver mutations, specifically activating mutations of the epidermal growth factor receptor (<em>EGFR</em>) and anaplastic lymphoma kinase (<em>ALK</em>) rearrangements, are particularly prone to development of brain metastases. Third, newer targeted therapies against <em>EGFR</em> and <em>ALK</em> have demonstrated far greater intracranial efficacy that permits careful consideration of systemic therapy as a preferred front-line approach over historically favored local therapies. Other novel systemic therapies, including immunotherapy, may also demonstrate sufficient intracranial activity to warrant a revision of historic practices.</p><p>These factors lead to evolving management options that are discussed in detail in this topic. An overview of the treatment of brain metastases as well as discussions of the clinical manifestations and diagnosis of brain metastases, management of seizures in patients with brain metastases, and overview of the treatment of advanced NSCLC are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases"</a> and  <a class="medical medical_review" href="/z/d/html/5217.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of brain metastases"</a> and  <a class="medical medical_review" href="/z/d/html/5182.html" rel="external">"Management of vasogenic edema in patients with primary and metastatic brain tumors"</a> and  <a class="medical medical_review" href="/z/d/html/5181.html" rel="external">"Seizures in patients with primary and metastatic brain tumors"</a> and  <a class="medical medical_review" href="/z/d/html/4607.html" rel="external">"Overview of the initial treatment of advanced non-small cell lung cancer"</a>.)</p><p class="headingAnchor" id="H1013265570"><span class="h1">EPIDEMIOLOGY OF BRAIN METASTASES IN NSCLC</span><span class="headingEndMark"> — </span>Among patients with lung cancer, 16 to 20 percent develop brain metastases. Incidence is higher in patients whose cancers harbor epidermal growth factor receptor (<em>EGFR</em>) mutation or anaplastic lymphoma kinase (<em>ALK</em>) rearrangement, in whom up to 50 to 60 percent will develop brain metastases over the course of their disease [<a href="#rid3">3-6</a>]. Although some, but not all, data have suggested patients with c-ROS oncogene 1 (<em>ROS1</em>)-positive NSCLC have lower rates of brain metastases than those with <em>ALK</em> rearrangements, the incidence in this subtype is approximately one-third [<a href="#rid7">7,8</a>].</p><p>It remains unclear whether this is because these patients have longer survival times and thus, more time to develop brain metastases, whether there is selective pressure and poor central nervous system (CNS) penetration of historically available targeted therapies, or whether these mutation-driven cancers have biologic features that predispose towards progression and growth within the CNS.</p><p class="headingAnchor" id="H3991795430"><span class="h1">PRESENTATION AND DIAGNOSIS</span><span class="headingEndMark"> — </span>The presenting symptoms and clinical manifestations of brain metastases that develop in the setting of NSCLC are the same as those for brain metastases in other settings. (See  <a class="medical medical_review" href="/z/d/html/5217.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of brain metastases"</a>.)</p><p class="headingAnchor" id="H3320142051"><span class="h1">GENERAL PRINCIPLES OF MANAGEMENT</span><span class="headingEndMark"> — </span>In general, the management of patients with advanced NSCLC and brain metastases is comparable to that for patients with brain metastases from other primary tumor sites. The main exception is for patients with a driver mutation, in whom newer-generation targeted systemic therapies have a higher likelihood of success against brain metastases than traditional chemotherapy or older targeted agents. (See <a class="local">'ALK translocations'</a> below and <a class="local">'EGFR mutations'</a> below.)</p><p>Targeted agents should not be used in the treatment of brain metastases for patients whose NSCLC does not harbor an activating mutation. For example, response to epidermal growth factor receptor (EGFR) inhibitors has been observed primarily in those whose tumors harbor an <em>EGFR</em> mutation rather than those whose tumors do not exhibit an <em>EGFR</em> mutation [<a href="#rid9">9-13</a>]. (See  <a class="medical medical_review" href="/z/d/html/4630.html" rel="external">"Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor", section on 'EGFR mutation as a predictor of responsiveness'</a>.)</p><p class="headingAnchor" id="H1371264986"><span class="h2">Monitoring of patients on systemic therapy</span><span class="headingEndMark"> — </span>Patients with brain metastases receiving systemic therapy should be monitored closely with magnetic resonance imaging (MRI), although the optimal frequency is unknown. We conduct surveillance imaging at an initial two- to three-month interval, and then increase it in patients demonstrating an intracranial response.</p><p class="headingAnchor" id="H1730795115"><span class="h2">Indications for steroids</span><span class="headingEndMark"> — </span>The role for steroids in the management of brain metastases of patients with advanced NSCLC is identical to that for patients with brain metastases from other primary tumor types. (See  <a class="medical medical_review" href="/z/d/html/5182.html" rel="external">"Management of vasogenic edema in patients with primary and metastatic brain tumors"</a>.)</p><p class="headingAnchor" id="H149027156"><span class="h2">Surgical intervention</span></p><p class="headingAnchor" id="H1580637434"><span class="h3">Severe mass effect or impending herniation</span><span class="headingEndMark"> — </span>For patients with severe mass effect or the threat of herniation, we favor an initial surgical approach, with subsequent systemic treatment depending on molecular characteristics of the tumor. The surgical management of brain metastases is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases", section on 'Efficacy of surgery'</a>.)</p><p class="headingAnchor" id="H2129275972"><span class="h3">Considerations in oligometastatic disease</span><span class="headingEndMark"> — </span>Importantly, a subset of patients with an isolated focus of "oligometastatic" disease, typically a single brain or adrenal metastasis, are amenable to resection of the primary chest tumor and local therapies to the solitary metastasis, administered with curative intent [<a href="#rid14">14,15</a>]. (See  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases", section on 'Single brain metastasis'</a>.)</p><p>Published series of patients with NSCLC with a solitary "precocious" metastasis to the brain have reported a long-term survival rate of approximately 25 percent [<a href="#rid15">15,16</a>], supporting a unique role for surgery or stereotactic radiosurgery in this setting [<a href="#rid16">16</a>]. A specific benefit of surgical management of a solitary brain metastasis is its diagnostic utility in confirming the diagnosis, tumor histology, and stage of the cancer (if malignancy is confirmed). Surgery should, however, be restricted to patients who are likely to survive the procedure and for whom recovery will not consume the remainder of their anticipated life expectancy.</p><p>Notably, because the molecular mutation patterns of brain metastases have been demonstrated to be discordant with those of the primary tumor in many patients [<a href="#rid17">17</a>], additional insights may be offered by obtaining tissue from an isolated brain metastasis. Brain metastases that develop in the setting of a first-generation EGFR tyrosine kinase inhibitor, such as <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a> or <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>, are less likely to be associated with development of acquired resistance mutations such as <em>EGFR</em> <em>T790M</em> than sites of extracranial progression [<a href="#rid17">17</a>]. This is presumably because brain metastases that develop while a patient is on a targeted agent with strong extracranial activity but relatively poor penetration into the central nervous system may be interpreted as having grown in a "sanctuary site" in which the cancer cells are not exposed to effective concentrations of the targeted therapy, in contrast with true acquired resistance to an active dose of that therapy. (See <a class="local">'Brain metastases upon progression on TKI'</a> below.)</p><p class="headingAnchor" id="H2925527247"><span class="h1">PATIENTS WITH ONCOGENIC DRIVERS</span></p><p class="headingAnchor" id="H4182291873"><span class="h2">Systemic therapy as initial treatment for ALK and EGFR-positive brain metastases</span><span class="headingEndMark"> — </span>For many patients with a driver mutation in epidermal growth factor receptor (<em>EGFR</em>) mutation or anaplastic lymphoma kinase (<em>ALK</em>) rearrangement, systemic therapy may now be utilized as an early intervention rather than the local therapies that have historically been favored. An important exception is for those with severe mass effect or impending herniation, in whom neurosurgical evaluation is indicated as the initial approach. We also note that other experts may reasonably continue to opt for radiation over targeted therapies, given that comparative data are limited and that the cognitive deficits associated with newer radiation modalities such as stereotactic radiation surgery (SRS) are small [<a href="#rid18">18</a>]. Discussion of surgery and radiation for brain metastases is found in other topics. (See  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases", section on 'Efficacy of surgery'</a> and  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases", section on 'Efficacy of SRS alone'</a> and  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases", section on 'Efficacy of WBRT'</a> and  <a class="medical medical_review" href="/z/d/html/7063.html" rel="external">"Stereotactic cranial radiosurgery"</a>.)</p><p>There are several specific reasons why systemic therapy may be particularly favored as an early intervention over local therapies. First, several of the systemic oral therapies directed against these molecular targets have demonstrated far greater intracranial activity than nontargeted therapies against brain metastases from tumors that harbor these driver mutations. Second, as a consequence of the marked efficacy of these targeted therapies, these very patients are increasingly likely to demonstrate a survival in the range of many years rather than only a few months, allowing time for cognitive deficits from previous local therapies, such as whole-brain radiation therapy (WBRT), to manifest [<a href="#rid19">19,20</a>]. Finally, limited observational data suggest similar time to progression and intracranial progression between patients receiving targeted therapy and radiation therapy (RT) versus targeted therapy alone [<a href="#rid21">21</a>].</p><p>According to guidelines from the American Society of Clinical Oncology, local therapy may be deferred in favor of targeted therapy in patients with asymptomatic brain metastases from oncogene-driven NSCLC, as part of a multidisciplinary discussion [<a href="#rid18">18</a>]; although we agree with this approach in general, we utilize targeted therapy over radiation even more liberally for those with brain metastases from <em>EGFR, </em>c-ROS oncogene 1<em> </em>(<em>ROS1</em>)<em>, </em>or <em>ALK</em>-mutated NSCLC, offering systemic therapy unless there are surgical indications or the patient experienced intracranial progression on a brain-penetrable inhibitor  (<a class="graphic graphic_algorithm graphicRef138727" href="/z/d/graphic/138727.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef138737" href="/z/d/graphic/138737.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef138738" href="/z/d/graphic/138738.html" rel="external">algorithm 3</a>). Multidisciplinary input is critical in optimizing treatment selection for individual patients.</p><p>Additional considerations for those who present with an isolated brain metastasis are discussed above. (See <a class="local">'Considerations in oligometastatic disease'</a> above.)</p><p class="headingAnchor" id="H3369934514"><span class="h2">ALK translocations</span><span class="headingEndMark"> — </span>For asymptomatic and symptomatic patients, <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">alectinib</a> or other brain-penetrable anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) may be used  (<a class="graphic graphic_algorithm graphicRef138738" href="/z/d/graphic/138738.html" rel="external">algorithm 3</a>). Most patients with brain metastases (either TKI-naϊve or on <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a>) will frequently respond to these agents [<a href="#rid21">21</a>], and surgery and/or RT may be deferred, thereby potentially reducing patient morbidity associated with these local treatments. However, in the case of severe mass effect or impending herniation, we proceed with surgery as the initial treatment [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases", section on 'Efficacy of surgery'</a>.)</p><p class="headingAnchor" id="H763346426"><span class="h3">Brain metastases at presentation</span><span class="headingEndMark"> — </span>In the front-line setting, <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">alectinib</a>, <a class="drug drug_general" data-topicid="112993" href="/z/d/drug information/112993.html" rel="external">brigatinib</a>, <a class="drug drug_general" data-topicid="119539" href="/z/d/drug information/119539.html" rel="external">lorlatinib</a>, and <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">ceritinib</a> are US Food and Drug Administration (FDA) approved [<a href="#rid24">24-26</a>]. Although ceritinib has demonstrated central nervous system (CNS) activity, it is less CNS penetrant than alectinib, brigatinib, and lorlatinib, and cross-trial comparisons suggest a lower durability of CNS response with ceritinib.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alectinib</strong> – Support for <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">alectinib</a> over <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a> as front-line treatment among those with brain metastases comes from phase III trials. In the J-ALEX study, among 43 crizotinib-naïve patients with ALK-positive NSCLC with brain metastases, alectinib demonstrated improved progression-free survival (PFS) relative to crizotinib (hazard ratio [HR] 0.08, 95% CI 0.01-0.61) [<a href="#rid27">27</a>]. Similarly, in the global ALEX study, among those with measurable CNS metastases, alectinib improved PFS relative to crizotinib (HR 0.40 95% CI 0.25-0.64), intracranial response rate (81 [95% CI 58-95] versus 50 [95% 28-72] percent), and duration of intracranial response (17.3 [95% CI 14.8-NR] versus 5.5 months [95% CI 2.1-17.3]). Further results of J-ALEX and ALEX are discussed elsewhere [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/4621.html" rel="external">"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer", section on 'Preferred options'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Brigatinib</strong> – <a class="drug drug_general" data-topicid="112993" href="/z/d/drug information/112993.html" rel="external">Brigatinib</a> has demonstrated efficacy over <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a> in the front-line setting, both systemically and in regards to CNS disease [<a href="#rid29">29</a>]. In the phase III ALTA-1L trial, of 275 patients with treatment-naïve, advanced, ALK-positive NSCLC, 90 had brain metastases at baseline, and 39 had measurable brain metastases (≥10 mm in diameter). The confirmed intracranial response rate among patients with baseline brain metastases was 78 percent with brigatinib versus 26 percent with crizotinib [<a href="#rid30">30</a>]. Brigatinib also improved PFS in this population (HR 0.25, 95% CI 0.14-0.46).</p><p></p><p class="bulletIndent1">In the entire patient population, <a class="drug drug_general" data-topicid="112993" href="/z/d/drug information/112993.html" rel="external">brigatinib</a> was associated with a lower rate of intracranial disease progression (9 versus 19 percent, respectively) [<a href="#rid29">29</a>]. Further results are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4621.html" rel="external">"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer", section on 'Brigatinib'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ceritinib</strong> – <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">Ceritinib</a> has been compared with platinum/<a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">pemetrexed</a> chemotherapy in the front-line setting but not with <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a>. Evidence of activity of ceritinib over chemotherapy in the front-line setting comes from the phase III ASCEND-4 trial of 376 treatment-naïve patients with advanced ALK-positive NSCLC, randomly assigned to either a platinum agent plus pemetrexed versus oral ceritinib [<a href="#rid31">31</a>]. Among the 44 patients with measurable brain metastases at baseline, the intracranial response among those receiving ceritinib was 73 (95% CI 49.8-89.3) versus 27 (95% CI 10.7-50.2) percent among those in the chemotherapy group. The median PFS for those with brain metastases receiving ceritinib was 10.7 versus 6.7 months among those receiving chemotherapy (HR 0.70, 95% CI 0.44-1.12). (See  <a class="medical medical_review" href="/z/d/html/4621.html" rel="external">"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer", section on 'Ceritinib'</a>.)</p><p></p><p class="bulletIndent1">Similarly, in preliminary results of ASCEND-7, which evaluated <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">ceritinib</a> in patients with newly diagnosed or progressive brain metastases, among 44 patients with no prior brain radiation or ALK inhibitor treatment, the whole-body objective response rate (ORR) was 59 percent, and the intracranial response rate was 52 percent, with a median duration of intracranial response of 7.5 months [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1">These ALK inhibitors have not been directly compared in terms of CNS or broader activity. However, based on cross-trial comparisons between ALEX and ASCEND-4, as well as the CNS activity of <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">alectinib</a> in small series of ceritinib-resistant patients [<a href="#rid33">33</a>], our preferred first-line agent for patients with brain metastases is either alectinib or off-label <a class="drug drug_general" data-topicid="112993" href="/z/d/drug information/112993.html" rel="external">brigatinib</a>, both of which are highly potent in the CNS compared with <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lorlatinib</strong> – In the phase III CROWN trial, 296 treatment-naïve patients with ALK-positive stage IIIB/IV NSCLC were randomly assigned to oral <a class="drug drug_general" data-topicid="119539" href="/z/d/drug information/119539.html" rel="external">lorlatinib</a> or <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a> [<a href="#rid34">34</a>]. Among 30 patients with measurable brain metastases, 14 of 17 patients (82 percent) assigned to lorlatinib and 3 of 13 patients (23 percent) in the crizotinib group had an intracranial response; furthermore, 12 patients (71 percent) who received lorlatinib had an intracranial complete response. Lorlatinib was associated with lower 12-month incidence of CNS progression compared with crizotinib, both in patients with (7 versus 72 percent) and without (1 versus 18 percent) brain metastases at baseline [<a href="#rid35">35</a>]. Further results of this trial are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4621.html" rel="external">"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer", section on 'Options under investigation in the first-line setting'</a>.)</p><p></p><p class="headingAnchor" id="H3503530157"><span class="h3">Brain metastases upon progression on TKI</span></p><p class="headingAnchor" id="H2262720032"><span class="h4">Crizotinib-resistant setting</span><span class="headingEndMark"> — </span>In patients previously treated with <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a>, either <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">alectinib</a>, <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">ceritinib</a>, or <a class="drug drug_general" data-topicid="112993" href="/z/d/drug information/112993.html" rel="external">brigatinib</a> are appropriate options [<a href="#rid29">29</a>], and are FDA approved in this setting [<a href="#rid24">24,25,36</a>]. <a class="drug drug_general" data-topicid="119539" href="/z/d/drug information/119539.html" rel="external">Lorlatinib</a> has been granted FDA approval for the treatment of patients with ALK-positive NSCLC who have progressed on crizotinib and at least one other ALK inhibitor, as well as for those who have progressed on either alectinib or ceritinib as front-line ALK inhibitor therapy for metastatic disease [<a href="#rid26">26</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alectinib</strong> – Evidence of the intracranial activity of <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">alectinib</a> in the <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a> resistant setting comes from the phase III ALUR trial, in which 107 patients with advanced ALK-positive NSCLC with progression after both crizotinib and platinum-based chemotherapy were randomly assigned to alectinib or single-agent chemotherapy [<a href="#rid37">37</a>]. Among the 24 patients with measurable baseline CNS disease, CNS ORR was higher with alectinib than chemotherapy (54 versus 0 percent, respectively). Full results from this study are discussed elsewhere.</p><p></p><p class="bulletIndent1">Further support for <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">alectinib</a> over chemotherapy comes from a pooled analysis of two phase II studies including 136 patients with baseline CNS metastases, 70 percent of whom had prior CNS RT [<a href="#rid22">22</a>]. In this analysis, the CNS ORR, disease control rate, and duration of response for alectinib were 43 percent, 85 percent, and 11.1 months, respectively [<a href="#rid22">22</a>]. Separately, in a retrospective study including 15 patients with large (≥1 cm) or symptomatic CNS metastases that were measurable, alectinib demonstrated a response rate of 72 percent [<a href="#rid38">38</a>]. Finally, alectinib has also demonstrated CNS activity in patients who have developed progressive brain or leptomeningeal metastases on <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">ceritinib</a> [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Brigatinib</strong> – <a class="drug drug_general" data-topicid="112993" href="/z/d/drug information/112993.html" rel="external">Brigatinib</a> is another acceptable option for crizotinib-resistant, ALK-positive patients with brain metastases [<a href="#rid39">39</a>], with the standard 180 mg dose (with lead-in), more active than the 90 mg daily dose [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="112993" href="/z/d/drug information/112993.html" rel="external">Brigatinib</a> has been tested in a phase I/II trial and a randomized phase II trial (ALTA1) in advanced ALK-positive NSCLC. In the phase I/II trial, which enrolled mostly crizotinib-pretreated patients, the intracranial response rate among 15 patients with measurable CNS metastases at baseline was 53 percent (95% CI 27-79) [<a href="#rid40">40</a>]. The phase II trial randomly assigned 222 crizotinib-pretreated patients to either 90 mg daily or to 180 mg daily (preceded by a one-week lead-in of 90 mg daily) [<a href="#rid29">29,41</a>]. Among 26 patients with measurable brain metastases who received brigatinib at 90 mg daily, the intracranial response rate was 50 percent [<a href="#rid41">41</a>]. Among 18 patients with measurable brain metastases who received brigatinib at 180 mg daily (with lead-in), the intracranial response rate was higher at 67 percent. Median duration of intracranial response was 9.4 and 16.6 months, for the low- and high-dose arms, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lorlatinib</strong> – <a class="drug drug_general" data-topicid="119539" href="/z/d/drug information/119539.html" rel="external">Lorlatinib</a> is a third-generation ALK/ROS1 inhibitor that is effective against <em>ALK</em> resistance mutations and is able to penetrate the blood-brain barrier [<a href="#rid26">26,42,43</a>]. In a phase II trial, among 81 patients who had previously been treated with at least one ALK inhibitor and had baseline brain metastases, the intracranial response rate was 63 percent, and median duration of intracranial response was 14.5 months [<a href="#rid26">26</a>]. In the preceding phase I trial of lorlatinib, the mean ratio of cerebrospinal fluid (CSF) to plasma lorlatinib concentrations was 0.75, confirming the significant CNS penetrability of lorlatinib [<a href="#rid42">42</a>]. In that trial, among 19 ALK-positive patients with measurable CNS disease, most of whom had received <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a> followed by a second-generation inhibitor such as <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">ceritinib</a>, <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">alectinib</a>, or <a class="drug drug_general" data-topicid="112993" href="/z/d/drug information/112993.html" rel="external">brigatinib</a>, the intracranial response rate was 42 percent (95% CI 20-67).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The phase II study of <a class="drug drug_general" data-topicid="119539" href="/z/d/drug information/119539.html" rel="external">lorlatinib</a> included six different expansion cohorts for ALK-positive patients based on prior treatment [<a href="#rid44">44</a>]. Among 37 patients previously treated with <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a> and with brain metastases at baseline, the intracranial response rate was 68 percent (95% CI 50-82). Among 83 patients previously treated with two or three ALK inhibitors, including at least one second-generation inhibitor, the intracranial response rate was 48 percent (95% CI 37-59). Activity of lorlatinib in treatment-naïve patients is discussed above. (See <a class="local">'Brain metastases at presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ceritinib</strong> – <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">Ceritinib</a> is an acceptable option for those with<em> </em>ALK-positive NSCLC and brain metastases, both in the front-line and crizotinib-resistant settings, although <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">alectinib</a>, <a class="drug drug_general" data-topicid="112993" href="/z/d/drug information/112993.html" rel="external">brigatinib</a>, and <a class="drug drug_general" data-topicid="119539" href="/z/d/drug information/119539.html" rel="external">lorlatinib</a> may be preferred. In a study of patients who previously progressed on <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a>, among 100 patients with baseline brain metastases, the intracranial response rate with ceritinib was 45 percent (95% CI 23-69 percent) [<a href="#rid45">45</a>]. In a separate study of patients with ALK-positive NSCLC and brain metastases, the intracranial response rates to ceritinib among patients with prior ALK inhibitor treatment and brain radiation was 39 percent, and among those with prior ALK inhibitors and no prior brain radiation it was 28 percent [<a href="#rid46">46</a>]. The median duration of response was 9.2 and 10.1 months in these two groups, respectively. (See <a class="local">'Brain metastases at presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other agents</strong> – Ensartinib (X-396) has also been reported to have activity against brain metastases. In a phase I/II study that enrolled both crizotinib-naïve and crizotinib-resistant patients, the intracranial response rate among 14 patients with baseline CNS metastases was 64 percent (95% CI 39-84) [<a href="#rid47">47</a>].</p><p></p><p class="headingAnchor" id="H3169812938"><span class="h4">Alectinib-resistant setting</span><span class="headingEndMark"> — </span>Data are evolving regarding management of patients who develop isolated intracranial progression on <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">alectinib</a> (CNS only recurrence with continued extracranial response). In this setting, the options include local therapy if only oligometastatic disease is present (one or a small number of lesions) or a switch to <a class="drug drug_general" data-topicid="119539" href="/z/d/drug information/119539.html" rel="external">lorlatinib</a>, which has documented CNS activity in patients whose cancer has progressed despite second-generation inhibitors. In the setting of limited data, a choice between these options depends on patient and provider preference as well as the availability of lorlatinib. (See <a class="local">'Crizotinib-resistant setting'</a> above.)</p><p>The management of patients who develop both intracranial and extracranial progression on <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">alectinib</a> is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4621.html" rel="external">"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer", section on 'Treatment after progression on second-generation ALK TKIs'</a>.)</p><p>In a case series of two ALK-positive patients who experienced initial improvements in CNS metastases on standard dose <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">alectinib</a> (600 mg twice daily) but who subsequently recurred with symptomatic leptomeningeal metastases, dose escalation to 900 mg twice daily resulted in repeat clinical and radiographic responses [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H2654407700"><span class="h2">EGFR mutations</span><span class="headingEndMark"> — </span>The management approach to brain metastases in patients with epidermal growth factor receptor (<em>EGFR</em>) mutation-positive NSCLC is in evolution at the present time. With the demonstrated CNS activity of <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> for patients with <em>EGFR</em>-positive NSCLC, more patients may now be able to achieve benefit from systemic therapy alone  (<a class="graphic graphic_algorithm graphicRef138727" href="/z/d/graphic/138727.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H1789008076"><span class="h3">Brain metastases at presentation</span></p><p class="headingAnchor" id="H455917454"><span class="h4">Preference for osimertinib</span><span class="headingEndMark"> — </span>We favor <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> as the initial management for patients presenting with brain metastases from <em>EGFR</em>-mutated NSCLC, except for those with impending herniation or severe mass effect. For patients lacking these indications for surgery, a closely monitored trial of an EGFR inhibitor in lieu of immediate RT is a reasonable approach.</p><p>Though this approach has not yet been tested in randomized trials, and retrospective data indicate that deferral of RT may be associated with worse outcomes compared with early RT [<a href="#rid49">49-56</a>], those studies were all conducted with first- or second-generation EGFR TKIs that have not demonstrated the intracranial activity seen thus far with <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a>. There are only limited data comparing osimertinib with local therapies for the management of brain metastases [<a href="#rid21">21</a>]; however, clinical data with osimertinib reveal encouraging activity against CNS disease, without the neurocognitive defects or postsurgical complications that may arise from brain irradiation or neurosurgery, respectively. Given the lack of data, however, some experts may reasonably opt instead for upfront RT, followed by osimertinib. (See  <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation", section on 'Neurocognitive effects'</a> and  <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation", section on 'Brain tissue necrosis'</a> and  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases", section on 'Complications of SRS'</a> and  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases", section on 'Early and delayed side effects'</a> and  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases", section on 'Risks and complications'</a>.)</p><p>In subset analysis of the FLAURA trial including 116 treatment-naïve patients with <em>EGFR-</em>mutated advanced NSCLC and CNS metastases, the PFS was longer for patients receiving <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> compared with those receiving either <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a> or <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> (15.2 versus 9.6 months; HR 0.47, 95% CI 0.30-0.74) [<a href="#rid57">57</a>]. In subsequent reporting, median CNS PFS among patients with measurable and/or non-measurable CNS lesions was not reached with osimertinib and was 13.9 months with standard EGFR TKI (HR 0.48, 95% CI 0.26-0.86) [<a href="#rid58">58</a>]. In addition, irrespective of baseline CNS disease, the rate of CNS progression in the overall study population of 556 patients was also lower with osimertinib (6 versus 15 percent) [<a href="#rid57">57</a>]. Among patients with brain metastases evaluable for response on FLAURA, the intracranial response rate was 91 percent with osimertinib, compared with 68 percent in recipients of a first-generation EGFR TKI.</p><p>Though first- and second-generation EGFR<em> </em>TKIs such as <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>, <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a>, and <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a> have antitumor activity in patients with brain metastases, [<a href="#rid9">9,10,13,59-62</a>], these agents are detected in the CSF only at low concentrations, in the 1 to 5 percent range of what is observed in the serum [<a href="#rid63">63-67</a>]. By contrast, <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> achieves greater intracranial concentrations [<a href="#rid68">68</a>] and has been demonstrated to have significant intracranial activity against brain metastases at the standard dose of 80 mg daily, and even against leptomeningeal carcinomatosis at 80 to 160 mg daily [<a href="#rid69">69,70</a>]. Discussion of leptomeningeal carcinomatosis is found separately. (See  <a class="medical medical_review" href="/z/d/html/5184.html" rel="external">"Treatment of leptomeningeal disease from solid tumors"</a>.)</p><p class="headingAnchor" id="H1561671538"><span class="h4">RT as an alternative, over earlier-generation TKIs</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">Osimertinib</a> achieves higher CSF concentrations and improved outcomes compared with earlier-generation tyrosine kinase inhibitors (TKIs), and therefore it is our preferred initial approach for those with <em>EGFR</em>-mutated NSCLC, even when CNS involvement is present. If osimertinib is not available, we offer radiation therapy (RT) as the initial approach for management for most cases of brain metastases from <em>EGFR</em>-positive NSCLC, with initiation of an earlier-generation TKI upon completion. An alternative option if osimertinib is not available is initiation of an earlier-generation TKI, which is appropriate for patients who either are not candidates for RT, or have asymptomatic, small-volume CNS disease and disseminated systemic disease. Although concurrent brain radiation and/or "pulsed" dosing with a higher dose of EGFR<em> </em>TKI therapy intermittently may achieve higher intracranial concentrations of EGFR<em> </em>TKIs, we do not endorse this approach, given the possibility of greater toxicity and as well as worsened outcomes [<a href="#rid56">56,65,66,71</a>].</p><p>Though limited by methodologic problems, a meta-analysis of 12 observational studies including 363 patients with <em>EGFR</em>-positive NSCLC and brain metastases suggested that, compared with initial treatment with a first-generation EGFR<em> </em>TKI, upfront cranial RT resulted in similar intracranial disease ORRs (relative risk [RR] 0.93, 95% CI 0.82-1.06), improved four-month intracranial disease PFS (RR 1.06, 95% CI 1.00-1.12), and improved two-year overall survival (OS; RR 1.33, 95% CI 1.00-1.77) but caused more neurologic toxicities than TKIs [<a href="#rid54">54</a>]. This conclusion is corroborated by a subsequent retrospective analysis of 351 patients with <em>EGFR</em> mutation-positive NSCLC and brain metastases who received initial SRS, WBRT, or EGFR TKI therapy, and experienced a median OS of 46, 30, and 25 months, respectively [<a href="#rid53">53</a>]. Though not a randomized trial and potentially limited by selection bias, multivariate analysis from this study suggested that SRS versus EGFR TKI as well as WBRT versus EGFR TKI were associated with improved survival, results which have also been supported by other studies [<a href="#rid51">51-54</a>].</p><p>Although in the absence of <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a>, we prefer RT as initial therapy for CNS disease, first- and second-generation EGFR TKIs alone have demonstrated some CNS activity. For example, several review papers have aggregated the findings supporting the intracranial activity of earlier-generation EGFR TKIs monotherapy [<a href="#rid72">72,73</a>], and descriptions of a few studies provide examples of the key results:</p><p class="bulletIndent1"><span class="glyph">●</span>A series of 53 evaluable patients with brain metastases from NSCLC included 17 patients with known <em>EGFR</em> mutations who were treated with <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> [<a href="#rid10">10</a>]. Eight of nine had an objective partial or complete response after treatment with erlotinib plus WBRT, while six of eight had an objective response to erlotinib alone. The remaining three patients had stable disease. In the entire group, the time to tumor progression in the brain was 11.7 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 41 Japanese patients with NSCLC with <em>EGFR</em> mutation and brain metastases, <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a> as monotherapy has demonstrated an ORR of 87.8 percent with OS of 21.9 months [<a href="#rid49">49</a>], supporting the use of EGFR TKIs as monotherapy without radiation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">Afatinib</a>, a second-generation irreversible EGFR inhibitor, has demonstrated CNS activity in the subgroup analysis of brain metastasis patients in the LUX-Lung 3 and 6 trials with increased intracranial PFS compared with chemotherapy (8.2 versus 5.4 months) [<a href="#rid74">74</a>].</p><p></p><p>As mentioned above, EGFR inhibitors should not be given in combination with WBRT. In a phase III study by the Radiation Therapy Oncology Group (RTOG 0302) that was stopped early due to slow accrual, 126 patients with NSCLC and one to three brain metastases were treated with WBRT plus SRS, WBRT plus SRS plus <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>, or WBRT plus SRS plus <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> [<a href="#rid56">56</a>]. OS was worse in each of the drug therapy arms compared with WBRT/SRS alone (13.4 months for WBRT/SRS versus 6.3 and 6.1 months for temozolomide and erlotinib, respectively), and toxicity was significantly higher in patients who received concurrent drug therapy.</p><p>In sum, available data suggest that EGFR TKIs demonstrate CNS activity in patients with <em>EGFR</em> mutation-positive NSCLC. However, among EGFR TKIs, <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> has demonstrated the greatest consistency in responses of brain metastases and prevention of disease progression within the CNS, making it the preferred treatment option, if available. (See <a class="local">'Preference for osimertinib'</a> above.)</p><p class="headingAnchor" id="H788943506"><span class="h3">Brain metastases upon progression on TKI</span><span class="headingEndMark"> — </span>The approach to progressive intracranial disease is discussed below, with considerations for situations in which progression occurs both systemically and in the CNS, versus intracranially only.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intracranial and extracranial progression</strong> – For those with progression on a first- or second-generation tyrosine kinase inhibitor (TKI), we obtain a tissue biopsy at progression from the most accessible extracranial site, or plasma for circulating tumor DNA. Further discussion of this methodology is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer", section on 'Liquid biopsies'</a>.)</p><p></p><p class="bulletIndent1">However, if urgent neurosurgical indications are present, an intracranial biopsy may be pursued. (See <a class="local">'Surgical intervention'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the <em>T790M</em> resistance mutation is found, we proceed with <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a>. If a <em>T790M</em> mutation is not found, management occurs in similar fashion as to those lacking an oncogenic driver mutation. (See <a class="local">'Patients lacking known oncogenic drivers'</a> below.)</p><p></p><p class="bulletIndent2">A planned subgroup analysis of the AURA3 trial evaluated CNS control with <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> versus chemotherapy in those with the acquired <em>T790M</em> resistance mutation [<a href="#rid75">75</a>]. In this trial, patients with <em>T790M</em> mutation-positive advanced NSCLC after progression on a prior EGFR TKI were randomly assigned to either osimertinib or <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>/<a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">pemetrexed</a> chemotherapy. Among the 46 patients with CNS lesions evaluable for response, the response rate was 70 versus 31 percent for osimertinib versus chemotherapy, respectively (OR 5.13, 95% CI 1.44-20.6). Looking at the preventive effect of these treatments in the full-analysis population of over 400 patients, the CNS PFS was also longer with osimertinib (11.7 versus 5.6 months; HR 0.32; 95% CI 0.15-0.69).</p><p></p><p class="bulletIndent2">Other evidence supporting use of <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> in the setting of <em>T790M-</em>positive NSCLC and brain metastases comes from earlier-phase studies and case reports. For example, pooled results from two phase II trials of osimertinib in <em>EGFR</em> <em>T790M</em> mutation-positive advanced NSCLC demonstrate an ORR and disease control rate of 54 and 92 percent, respectively, among the 50 patients with baseline brain metastases that were evaluable for measurement of response [<a href="#rid76">76</a>]. Intracranial efficacy is also reflected in several case reports that have documented rapid and dramatic responses of brain metastases in patients who have received standard-dose osimertinib [<a href="#rid77">77,78</a>].</p><p></p><p class="bulletIndent2">Separately, a single-arm study evaluating <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> 160 mg in patients with <em>T790M</em>-positive brain metastases described an intracranial ORR and disease control rate of 55 and 78 percent, respectively [<a href="#rid79">79</a>]. Promising activity was also observed among patients with leptomeningeal disease. (See  <a class="medical medical_review" href="/z/d/html/5184.html" rel="external">"Treatment of leptomeningeal disease from solid tumors", section on 'Patients with non-small cell lung cancer'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who develop progression on <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a>, we treat along similar lines as for those without an oncogenic driver mutation. (See <a class="local">'Patients lacking known oncogenic drivers'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isolated intracranial progression</strong> – In the setting where patients exhibit good extracranial disease control but intracranial progression, it is unclear whether the intracranial disease represents true acquired resistance versus a "sanctuary" site, with inadequate exposure to the EGFR TKI. The fact that brain metastases are significantly less likely than extracranial sites of progression to harbor the <em>T790M</em> acquired resistance mutation suggests the interpretation of inadequate CNS penetration. This is particularly true for first- and second-generation EGFR TKIs, such as <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a>, <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>, and <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who develop isolated intracranial progression on a first- or second-generation EGFR TKI, we transition to <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a>. Switching to osimertinib may obviate the need for local therapy and significantly reduce the risk of further CNS progression compared with continuation of the original earlier-generation EGFR TKI.</p><p></p><p class="bulletIndent1">However, <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> is FDA approved in the second-line setting only for patients with the acquired resistance mutation <em>T790M</em> (which is less commonly seen in the setting of intracranial versus extracranial progression [<a href="#rid17">17</a>]). As such, some experts may prefer to continue systemic treatment with an earlier-generation TKI for patients with isolated intracranial progression on such an agent, reserving osimertinib for possible later treatment of <em>T790M</em>-mediated resistance. In such cases or when osimertinib is not available, it is acceptable to use local therapy for the brain metastases and continue the current EGFR TKI. If this option is chosen, the original TKI may be continued until either progression of extracranial disease, or progression of intracranial disease after local therapies have been applied.</p><p></p><p class="bulletIndent1">As a second alternative strategy, one may pursue brain biopsy, with subsequent transition to <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> if <em>T790M</em> is uncovered, versus local therapy to the brain metastases and continuation of the original TKI if <em>T790M</em> is not found.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who develop isolated intracranial progression on <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> and continue to demonstrate good extracranial disease control, we favor management of the brain metastases with local therapy as indicated, with no change in systemic therapy from osimertinib.</p><p></p><p class="headingAnchor" id="H1097140332"><span class="h2">Other oncogenic drivers</span><span class="headingEndMark"> — </span>Targeted agents have shown promising activity for other oncogenic drivers as well, although data are more limited than for <em>EGFR </em>and <em>ALK</em>, and as such, we typically suggest local treatment strategies in addition to systemic therapy, rather than systemic therapy alone.</p><p class="headingAnchor" id="H3852276995"><span class="h3">ROS1 translocations</span><span class="headingEndMark"> — </span>For patients with c-ROS oncogene 1 (<em>ROS1</em>)-rearranged NSCLC and brain metastases, the optimal first-line treatment has not been established. For patients with small, asymptomatic brain metastases, we proceed with systemic therapy using <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">entrectinib</a>, or, if unavailable, <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a>  (<a class="graphic graphic_algorithm graphicRef138737" href="/z/d/graphic/138737.html" rel="external">algorithm 2</a>) [<a href="#rid80">80</a>], with close surveillance of symptoms and brain imaging. For patients with larger or symptomatic brain metastases, we favor either local approaches (RT or surgery) followed by systemic therapy, or referral to a clinical trial of a next-generation, CNS-penetrant ROS1 inhibitor. If RT is being considered, we prefer, if possible, stereotactic radiosurgery (SRS) over WBRT. (See  <a class="medical medical_review" href="/z/d/html/7063.html" rel="external">"Stereotactic cranial radiosurgery", section on 'SRS versus conventional RT'</a> and  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases", section on 'Efficacy of SRS alone'</a>.)</p><p><a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">Entrectinib</a>, a potent ROS1/tropomyosin receptor kinase (TRK) inhibitor, has demonstrated CNS activity in crizotinib-naïve, <em>ROS1</em>-positive patients [<a href="#rid81">81</a>]. In a pooled analysis of three studies including 24 patients with measurable baseline CNS metastases, the intracranial ORR was 79 percent, the median intracranial PFS was 12.0 months, and the median intracranial duration of response was 12.9 months [<a href="#rid82">82</a>]. Earlier data from these trials have led to the approval of entrectinib for patients with <em>ROS1</em>-translocated NSCLC (irrespective of line of treatment or presence of intracranial disease) [<a href="#rid81">81,83</a>]. Based on its excellent overall efficacy and superior activity within the CNS, it is our preferred first-line option for patients with <em>ROS1</em>-positive NSCLC and brain metastases. For those with <em>ROS1</em>-positive NSCLC without brain metastases, either entrectinib or <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a> are appropriate options, although CNS relapses on crizotinib may be seen due to its poor CNS penetration [<a href="#rid8">8</a>]. <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">Ceritinib</a> also appears to be effective for those with intracranial disease from <em>ROS1</em>-positive NSCLC. In a phase II study of ceritinib in crizotinib-naïve, <em>ROS1</em>-positive NSCLC, two patients had measurable CNS disease at baseline, and one of the two demonstrated an intracranial response to ceritinib [<a href="#rid84">84</a>]. (See  <a class="medical medical_review" href="/z/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer", section on 'ROS1 rearrangements'</a>.)</p><p>For patients who have relapsed on front-line <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a> (intracranially and/or extracranially), the third-generation ALK/ROS1 inhibitor <a class="drug drug_general" data-topicid="119539" href="/z/d/drug information/119539.html" rel="external">lorlatinib</a> is appropriate, in the absence of severe mass effect or risk of herniation (although lorlatinib is off-label in this setting). Overall, though studies are limited by small numbers and even smaller subsets of patients with brain metastases, available data support a high degree of intracranial activity with lorlatinib. In the phase I study of lorlatinib, three of five patients (60 percent) had intracranial objective responses, two of whom had experienced disease progression on prior crizotinib [<a href="#rid42">42</a>]. Similarly, in the phase II study of lorlatinib, among 11 <em>ROS1</em>-positive patients with baseline brain metastases who were crizotinib naïve, the intracranial response rate was 63 percent [<a href="#rid85">85</a>]; among 24 patients with baseline brain metastases who had been treated with crizotinib as their only previous<em> </em>ROS1 TKI, intracranial response rate was 51 percent.</p><p>The investigational agent <a class="drug drug_general" data-topicid="143455" href="/z/d/drug information/143455.html" rel="external">repotrectinib</a> is promising for patients with <em>ROS1</em>-positive NSCLC. In preliminary data, among three TKI-naϊve patients with measurable baseline CNS disease, the intracranial ORR was 100 percent (three of three); among four patients with measurable baseline CNS disease who had previously received treatment with a TKI, the ORR was 50 percent (two of four) [<a href="#rid86">86</a>]. In both groups, the median duration of response was 5.5 months.</p><p>In the event of CNS progression despite systemic therapies, we proceed to radiation or, less commonly, surgery, if clinically appropriate.</p><p class="headingAnchor" id="H2621093589"><span class="h3">MET exon-14-skipping mutations</span><span class="headingEndMark"> — </span>For those with a <em>MET</em> exon-14-skipping mutation and brain metastases from NSCLC, we suggest <a class="drug drug_general" data-topicid="128126" href="/z/d/drug information/128126.html" rel="external">capmatinib</a>, which is approved by the FDA [<a href="#rid87">87</a>]. Capmatinib is a highly selective and potent MET inhibitor that crosses the blood-brain barrier. <a class="drug drug_general" data-topicid="130698" href="/z/d/drug information/130698.html" rel="external">Tepotinib</a> is another FDA-approved agent for patients with <em>MET </em>exon-14-skipping mutations [<a href="#rid88">88</a>]. Though intracranial activity is not well characterized, it demonstrates intracranial activity in patients with brain metastases [<a href="#rid89">89</a>].</p><p>However, for patients with tumors that are <em>MET</em> amplified only, we proceed with local therapies and immunotherapy/chemotherapy first, rather than a MET inhibitor, given fewer supporting data for these agents in such cancers.</p><p>In preliminary results of the GEOMETRY-mono-1 trial including 97 patients with advanced NSCLC associated with a <em>MET</em> exon-14-skipping mutation, there were 13 patients with evaluable baseline brain metastases, per independent review committee [<a href="#rid90">90</a>]. Upon treatment with <a class="drug drug_general" data-topicid="128126" href="/z/d/drug information/128126.html" rel="external">capmatinib</a>, 7 of the 13 patients (54 percent) had intracranial response, four of whom had complete resolution of all brain lesions. Three of the seven responders had prior brain radiotherapy; five of the seven responders had either signs of progression in the existing brain lesion(s) or new brain metastases at study entry. Intracranial disease control (stable or responding disease) was achieved in 12 of 13 patients.</p><p><a class="drug drug_general" data-topicid="130698" href="/z/d/drug information/130698.html" rel="external">Tepotinib</a> is an alternative option in this setting. In the VISION trial, among the 11 patients with brain metastases (all of which were nontarget tumors), the response rate to tepotinib was 55 percent, with a median duration of response of 9.5 months [<a href="#rid89">89</a>].</p><p class="headingAnchor" id="H2492124237"><span class="h3">RET fusions</span><span class="headingEndMark"> — </span>For patients with advanced NSCLC with a <em>RET</em> rearrangement and brain metastases, we suggest either <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">selpercatinib</a> or <a class="drug drug_general" data-topicid="129470" href="/z/d/drug information/129470.html" rel="external">pralsetinib</a>, both of which are approved by the FDA [<a href="#rid91">91,92</a>].</p><p>In a randomized phase III trial including 29 patients with measurable brain metastases at baseline that were either asymptomatic or had been neurologically stable for at least two weeks, <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">selpercatinib</a> resulted in an intracranial response that occurred in 82 versus 58 percent in the control group (platinum-based chemotherapy, with or without <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, at the investigator's discretion) [<a href="#rid93">93</a>]. At 12 months 76 percent continued to have a response with selpercatinib, versus 63 percent in the control group. Further results of this trial are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer", section on 'RET rearrangements'</a>.)</p><p>Similarly, in the previous multicohort, open-label, phase I/II LIBRETTO-001 study, responses in intracranial lesions were observed in 85 percent of the patients with measurable disease [<a href="#rid94">94,95</a>]. Objective responses were observed regardless of whether patients had received prior systemic therapy and/or radiotherapy. Among the 22 patients with CNS response, median duration of CNS response was 9.4 months.</p><p><a class="drug drug_general" data-topicid="129470" href="/z/d/drug information/129470.html" rel="external">Pralsetinib</a> is another FDA-approved RET inhibitor with intracranial activity, with intracranial response rate of 80 percent (7 of 9 patients) in those with baseline measurable intracranial metastases in an early-phase clinical study [<a href="#rid96">96</a>].</p><p class="headingAnchor" id="H950677426"><span class="h3">KRAS G12C</span><span class="headingEndMark"> — </span>For patients with advanced NSCLC with a <em>KRAS </em>G12C rearrangement and brain metastases, we suggest <a class="drug drug_general" data-topicid="140357" href="/z/d/drug information/140357.html" rel="external">adagrasib</a> or <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">sotorasib</a> as an initial systemic treatment strategy. Examples of available data are below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adagrasib</strong> – In a single arm trial (KRYSTAL-1) in 19 patients with <em>KRAS</em><em><sup>G12C</sup></em>-mutated NSCLC and untreated measurable CNS disease, <a class="drug drug_general" data-topicid="140357" href="/z/d/drug information/140357.html" rel="external">adagrasib</a> was associated with an intracranial objective response rate of 42 percent, PFS of 5.4 months, and median OS of 11.4 months [<a href="#rid97">97</a>]. Grade 3 treatment related events occurred in 10 patients (40 percent), with one grade 4 event (4 percent), and no grade 5 events. The most common CNS-specific treatment related adverse events were dysgeusia (24 percent) and dizziness (20 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sotorasib</strong> – In a presented abstract of a phase I/II study including 40 patients with stable brain metastases, 65 percent of had received prior radiotherapy and 20 percent had prior brain surgery [<a href="#rid98">98</a>]. Among 16 patients with baseline and at least one scan on treatment, intracranial disease control (stable or responding disease) was achieved in 88 percent. <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">Sotorasib</a> was associated with a median PFS and OS of 5.3 and 8.3 months in NSCLC patients with stable BM previously treated with radiation or surgery.</p><p></p><p>Given these results, these targeted agents are our suggested initial strategy for most patients with intracranial disease lacking indications for neurosurgical intervention; however, initial radiation followed by <a class="drug drug_general" data-topicid="140357" href="/z/d/drug information/140357.html" rel="external">adagrasib</a> is an acceptable alternative, as there are no randomized trials comparing these strategies in this setting. (See <a class="local">'Systemic therapy as initial treatment for ALK and EGFR-positive brain metastases'</a> above.)</p><p class="headingAnchor" id="H1296792595"><span class="h2">Sequencing of TKI with local therapies</span><span class="headingEndMark"> — </span>For those with intracranial involvement treated with initial targeted therapy only (ie, no initial local therapy), we continue the targeted agent until evidence of progression, either systemically or intracranially. At that point, we proceed with local management of intracranial disease, with choice between radiation and surgery dependent on extent of the disease. (See <a class="local">'Surgical intervention'</a> above.)</p><p>However, for patients who are undergoing local therapy as part of the initial management strategy for intracranial disease, consideration must be given to timing of TKIs in relation to local treatment. For patients who undergo neurosurgery for brain metastases, it is reasonable to start or resume a tyrosine kinase inhibitor (TKI) as early as one to two days after surgery, presuming that oral medications can be tolerated.</p><p>For patients who will receive radiation, we routinely favor holding the TKI until completion of therapy, unless a patient has such extensive tumor burden and cancer-related symptoms that withholding systemic therapy for one to several weeks risks significant deterioration. This is to decrease the risk of cognitive complications. For example, although some evidence suggests that <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> can be safely administered with concurrent WBRT [<a href="#rid55">55</a>], other data suggest a potentially greater risk of cognitive complications with concurrent EGFR TKI and WBRT [<a href="#rid99">99</a>]. Similarly, for those treated with SRS, we typically recommend holding the TKI and resuming the day after SRS is completed, given an absence of data to speak to the safety of TKI therapy with concurrent SRS.</p><p class="headingAnchor" id="H2654241797"><span class="h1">PATIENTS LACKING KNOWN ONCOGENIC DRIVERS</span></p><p class="headingAnchor" id="H1023513532"><span class="h2">Preference for initial RT, followed by systemic therapy</span><span class="headingEndMark"> — </span>In our practice, our approach is as follows  (<a class="graphic graphic_algorithm graphicRef138728" href="/z/d/graphic/138728.html" rel="external">algorithm 4</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>We offer local therapy with radiation therapy (RT) for most patients with good performance status and brain metastases. Subsequent to local management of brain metastases, we proceed with systemic therapy. There are some patients, however, in whom RT is not the optimal initial management:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who present with disseminated lung cancer and asymptomatic brain metastases, chemotherapy rather than RT has been proposed as an alternative, using a regimen specific for lung cancer. (See <a class="local">'Chemotherapy, with or without immunotherapy'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those with poor performance status, best supportive care (BSC), including steroids, is an appropriate option. (See <a class="local">'Best supportive care'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those with severe mass effect or impending herniation, a surgical approach is indicated. (See  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases", section on 'Efficacy of surgery'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chemotherapy also appears to be less effective than RT for brain metastases that have been previously irradiated, and therefore we prefer repeat RT for most patients in this setting, if felt to be safe and feasible.</p><p></p><p>In general, practice has shifted away from routine whole-brain radiation therapy (WBRT) and toward stereotactic radiosurgery (SRS) for patients with a limited number of brain metastases. This broad topic is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases", section on 'Patients with good performance status'</a>.)</p><p>For patients in whom whole brain radiation therapy is indicated, however, approaches to minimize cognitive decline such as use of <a class="drug drug_general" data-topicid="10131" href="/z/d/drug information/10131.html" rel="external">memantine</a> or hippocampal sparing may be appropriate for some. Indications for WBRT and use of interventions to decrease associated cognitive decline are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases", section on 'High tumor burden or multiple large tumors'</a> and  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases", section on 'Hippocampal avoidance and memantine'</a>.)</p><p class="headingAnchor" id="H151658171"><span class="h2">Alternatives</span></p><p class="headingAnchor" id="H106550468"><span class="h3">Chemotherapy, with or without immunotherapy</span><span class="headingEndMark"> — </span>NSCLC lacking a driver mutation is less responsive to systemic therapy than oncogene addicted cancers. As such, for most patients lacking a targetable driver mutation, we treat intracranial disease initially with RT, followed by systemic therapy. However, an exception is for those with disseminated NSCLC and asymptomatic brain metastases, whom we treat with a lung cancer-specific chemoimmunotherapy regimen, rather than with RT, in efforts to control systemic progression while potentially managing intracranial disease. In such cases, RT may be reserved as a later option in the event of subsequent progression of brain metastases. (See  <a class="medical medical_review" href="/z/d/html/4629.html" rel="external">"Subsequent line therapy in non-small cell lung cancer lacking a driver mutation"</a>.)</p><p>For patients with nonsquamous cancers with untreated, asymptomatic brain metastases, the combination of <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> and <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">pemetrexed</a> is an acceptable alternative to radiation. In a single-arm phase II trial in 40 patients with advanced nonsquamous NSCLC with asymptomatic brain metastases, atezolizumab plus carboplatin and pemetrexed was associated with an intracranial median PFS of 6.9 months and response rate of 43 percent [<a href="#rid100">100</a>]. Systemic median PFS was 8.9 months and response rate was 45 percent. The median overall survival (OS) was 11.8 months, and the two-year OS rate was 28 percent. While these results are promising, this strategy has not been compared with upfront radiation.</p><p>Chemotherapy alone has also been evaluated in patients with brain metastases. In a randomized pilot trial involving 48 neurologically asymptomatic patients, no significant differences in response rate or survival were observed when patients were treated with chemotherapy (<a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">vinorelbine</a> plus <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a>) followed by RT rather than with RT followed by chemotherapy [<a href="#rid101">101</a>].</p><p>Response rates of brain metastases to chemotherapy are highest in patients who had not received prior systemic treatment or RT. In a series of 43 previously untreated patients with NSCLC, the objective response rate to the combination of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> was 30 percent, and the median survival was 32 weeks [<a href="#rid102">102</a>]. Other platinum-based regimens have given similar response rates in previously untreated patients [<a href="#rid103">103-105</a>]. <a class="drug drug_general" data-topicid="10007" href="/z/d/drug information/10007.html" rel="external">Topotecan</a> and <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">pemetrexed</a> also have single-agent activity [<a href="#rid106">106,107</a>]. <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">Temozolomide</a> is an option for further-line therapy, though data have been mixed regarding its activity, with response rates ranging from 0 to 20 percent [<a href="#rid108">108-113</a>].</p><p class="headingAnchor" id="H3220609470"><span class="h3">Immunotherapy monotherapy</span><span class="headingEndMark"> — </span>Treatment with immune checkpoint inhibitors such as the programmed cell death protein 1 (PD-1) antibody <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> is now routinely administered as first-line treatment with chemotherapy to patients with nonsquamous NSCLC, or as monotherapy for squamous or nonsquamous NSCLC in patients whose tumors express high-level expression of programmed cell death ligand 1 (PD-L1). In addition, several immune checkpoint inhibitors directed against PD-1 or PD-L1 (including <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, pembrolizumab, and <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a>) are approved for the majority of patients with advanced NSCLC previously treated with conventional chemotherapy. Accordingly, most patients with advanced NSCLC and brain metastases are eligible to receive an immune checkpoint inhibitor in the first-line or later setting, either alone or potentially concurrent with chemotherapy. These indications are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation"</a>.)</p><p>Although rapidly evolving, present data are limited with immune checkpoint inhibitors for brain metastases from advanced NSCLC. Therefore, other treatments directed against intracranial disease should be pursued in most patients. For patients receiving intracranial RT for brain metastases and on immunotherapy for extracranial disease, we continue immunotherapy concurrently with radiation, though we recognize supporting data are retrospective [<a href="#rid114">114-116</a>], and that prospective studies are required to confirm that there are no increased toxicities associated with this approach. Alternatively, some experts may opt to delay RT and treat patients with small-volume, asymptomatic brain metastases with immunotherapy (with or without conventional chemotherapy), particularly if predictive markers such as PD-L1 expression indicate a higher probability of response.</p><p>Patients with active CNS disease have largely been excluded from most trials with checkpoint inhibitors. However, available evidence provides a proof of principle that PD-1 or PD-L1 immune checkpoint inhibitors as monotherapy can induce objective intracranial responses in patients with brain metastases from advanced NSCLC, on the order of approximately 30 percent [<a href="#rid117">117-119</a>], with greater levels of PD-L1 expression correlating with higher likelihood of response. Responses appear to be durable to the extent of the limited follow-up thus completed and typically concordant with extracranial responses to immunotherapy, with one retrospective study of 255 patients with brain metastases on immune checkpoint inhibitors reporting discordant cranial-extracranial response in 13 percent [<a href="#rid117">117</a>]. However, the extracranial efficacy of such agents remains confined to a minority of patients with advanced NSCLC overall, in particular the roughly 30 percent of patients whose tumors have high-level PD-L1 expression. Representative data are summarized:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pembrolizumab</strong> – An open-label, phase II trial of patients with NSCLC with untreated brain metastases demonstrated activity of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, with 11 of 37 (30 percent) patients with PD-L1-positive tumors experiencing objective CNS responses, and 0 of 5 (0 percent) of those with PD-L1-negative tumors experiencing CNS responses [<a href="#rid119">119</a>]. Patients were not permitted to have neurologic symptoms or require steroids, and those whose tumors expressed oncogenic variants previously associated with low response rates to checkpoint inhibitor therapy (eg, epidermal growth factor receptor [<em>EGFR</em>], anaplastic lymphoma kinase [<em>ALK</em>], or human epidermal growth factor receptor 2 [<em>HER2</em>] mutations) were excluded. In the PD-L1-positive cohort, responses were concordant with extracranial objective responses in nearly 80 percent of cases that were evaluable for both CNS and systemic responses. CNS responses were durable over the limited interval of follow-up (one-third of patients with CNS responses were progression free in the CNS at one year).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nivolumab</strong> – Analysis of the <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> expanded-access program in Italy identified 372 squamous NSCLC patients, of whom 38 had asymptomatic brain metastases [<a href="#rid120">120</a>]. The disease control rate was 39 percent. Median progression-free survival and OS in brain metastasis patients were 5.5 and 6.5 months, respectively [<a href="#rid121">121</a>]. A small series of five patients with NSCLC brain metastases treated with nivolumab has demonstrated activity in three of the cases [<a href="#rid122">122</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atezolizumab</strong> – Preliminary presentation of pooled data of patients enrolled in one of five treatment studies with the PD-L1 inhibitor <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> suggests that atezolizumab is well tolerated and active in NSCLC patients with brain metastases [<a href="#rid123">123</a>]. No treatment-related grade 4 or 5 neurologic adverse events were seen in patients with brain metastases (n = 79). In one of the trials included in this analysis, among patients with baseline brain metastases, there was a nonsignificant trend towards reduction in the risk of developing new CNS lesions with atezolizumab compared with <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> (hazard ratio [HR] 0.42, 95% CI 0.15-1.18).</p><p></p><p>Although initial data are promising, we await further studies to determine whether patients with brain metastases from NSCLC who lack an oncogenic driver mutation can safely defer local therapies in favor of immune checkpoint inhibitor therapy.</p><p class="headingAnchor" id="H4011454139"><span class="h3">Best supportive care</span><span class="headingEndMark"> — </span>A leading concern about WBRT has been the potential cognitive toxicity and other morbidities of this approach, along with the limited survival of patients who have undergone WBRT, even with modern techniques [<a href="#rid124">124</a>]. For patients with baseline poor performance status, BSC and steroids are an appropriate alternative to RT.</p><p>The QUARTZ trial, which randomized patients with advanced NSCLC and brain metastases to <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> and BSC with or without WBRT, has raised particular questions about the role of WBRT in this setting [<a href="#rid125">125</a>]. The trial revealed no significant difference in OS or quality of life (QOL) between the two groups.</p><p>Though these results failed to demonstrate a clear clinical benefit with WBRT, the shortcomings of the study are profound and limit the generalizability of the conclusions. Specifically, the median OS was only approximately two months in both arms, only a few weeks longer than the duration of treatment, suggesting that a large proportion of the patients were too debilitated to benefit from significant interventions. In addition, a very prolonged duration of enrollment suggests that participating centers exercised significant selection bias, specifically favoring for referral to the QUARTZ trial a limited subset of patients in whom the investigators felt it appropriate to potentially randomize to steroids and supportive care alone. Subset analysis of the QUARTZ trial revealed an improved survival with WBRT in younger patients, specifically those under the age of 60, along with a trend toward more favorable outcomes in patients with a Karnofsky performance status of 70 or higher and NSCLC with controlled primary disease.</p><p>The results of the QUARTZ trial highlight that WBRT does not confer a significant benefit in either OS or QOL in patients who are older and/or have a compromised performance status. Concerns about selection bias, combined with the overall remarkably poor outcomes of patients on both arms of this trial, however, lead many to feel that these conclusions are not generalizable. In particular, they may not apply to patients with a better performance status, younger age, and/or better control of extracranial disease.</p><p class="headingAnchor" id="H3466994754"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H3294148846"><span class="h2">Medically frail</span><span class="headingEndMark"> — </span>In general, the management approach for frail patients with advanced NSCLC and brain metastases is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases", section on 'Patients with poor performance status'</a>.)</p><p>As noted above, patients with a driver mutation, such as an anaplastic lymphoma kinase (<em>ALK</em>) rearrangement or epidermal growth factor receptor (<em>EGFR</em>) mutation, can demonstrate dramatic and prolonged responses of both extracranial and intracranial tumor burden to newer tyrosine kinase inhibitors (TKIs) directed against these targets, often with favorable tolerability. Accordingly, medically frail patients with brain metastases in whom one of these driver mutations is detected may be strong candidates for initial treatment with one of these targeted therapies, particularly if brain metastases are asymptomatic. (See <a class="local">'Patients with oncogenic drivers'</a> above.)</p><p>For frail patients without a driver mutation, stereotactic radiosurgery (SRS) may be feasible. While whole-brain radiation therapy (WBRT) remains an option, the results of the QUARTZ trial suggest that patients with NSCLC and brain metastases may realize little or no benefit from WBRT, a finding that is likely particularly relevant for patients with a marginal or poor performance status [<a href="#rid125">125</a>]. (See <a class="local">'Best supportive care'</a> above.)</p><p class="headingAnchor" id="H1341890804"><span class="h2">Leptomeningeal disease</span><span class="headingEndMark"> — </span>The general approach to patients with leptomeningeal disease is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5184.html" rel="external">"Treatment of leptomeningeal disease from solid tumors"</a>.)</p><p>Many targeted agents have shown efficacy in patients with leptomeningeal disease, for example, <a class="drug drug_general" data-topicid="119539" href="/z/d/drug information/119539.html" rel="external">lorlatinib</a> and <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">alectinib</a> for ALK-positive cancers [<a href="#rid126">126,127</a>] and <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">selpercatinib</a> in RET-fusion cancers [<a href="#rid128">128</a>]. For those with <em>EGFR</em>-mutated tumors and leptomeningeal disease, <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> has demonstrated significant intracranial activity against brain metastases at 80 to 160 mg daily [<a href="#rid69">69,70,129</a>]. (See  <a class="medical medical_review" href="/z/d/html/5184.html" rel="external">"Treatment of leptomeningeal disease from solid tumors", section on 'Patients with non-small cell lung cancer'</a>.)</p><p class="headingAnchor" id="H3202580115"><span class="h2">Considerations during the COVID-19 pandemic</span><span class="headingEndMark"> — </span>The COVID-19 pandemic has increased the complexity of cancer care. Important issues include balancing the risk from treatment delay versus harm from COVID-19, ways to minimize negative impacts of social distancing during care delivery, and appropriately and fairly allocating limited health care resources. These and recommendations for cancer care during active phases of the COVID-19 pandemic are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/128993.html" rel="external">"COVID-19: Considerations in patients with cancer"</a>.)</p><p class="headingAnchor" id="H2183694903"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112231.html" rel="external">"Society guideline links: Diagnosis and management of lung cancer"</a>.)</p><p class="headingAnchor" id="H2861381020"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – Brain metastases are a common complication in a wide range of cancers, but they are particularly common among patients with lung cancer. Approximately 10 percent of newly diagnosed patients with advanced non-small cell lung cancer (NSCLC) have brain metastases. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with severe mass effect or risk of herniation</strong> – For patients <strong>with </strong>severe mass effect or the threat of herniation, we favor a surgical approach initially, with subsequent systemic treatment depending on molecular characteristics of the tumor. The surgical management of brain metastases is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases", section on 'Efficacy of surgery'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with oncogenic drivers, lacking surgical indications</strong> – For patients <strong>without</strong> severe mass effect or the threat of herniation, the initial approach depends upon whether an oncogenic driver mutation is present and whether a central nervous system (CNS)-penetrant tyrosine kinase inhibitor (TKI) is available  (<a class="graphic graphic_algorithm graphicRef138738" href="/z/d/graphic/138738.html" rel="external">algorithm 3</a> and <a class="graphic graphic_algorithm graphicRef138737" href="/z/d/graphic/138737.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef138727" href="/z/d/graphic/138727.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef138728" href="/z/d/graphic/138728.html" rel="external">algorithm 4</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Targetable driver mutations</strong> – For those with brain metastases from advanced NSCLC associated with the targetable driver mutations discussed above (anaplastic lymphoma kinase [<em>ALK</em>] or epidermal growth factor receptor [<em>EGFR</em>]<em> </em>mutations, we suggest targeted therapy as an initial approach, rather than radiation or surgery (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), given evidence of high intracranial activity in trials. However, these therapies have not been compared directly with radiation therapy (RT) or surgery, and RT therefore remains an appropriate alternative. (See <a class="local">'Patients with oncogenic drivers'</a> above.)</p><p></p><p class="bulletIndent2">For those with brain metastases from c-ROS oncogene 1 [<em>ROS1</em>] translocations<em>, MET</em> exon-14-skipping mutations, <em>RET</em> fusions, or <em>KRAS G12C, </em>we typically suggest multimodal treatment including radiation followed by systemic therapy rather than systemic therapy alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">Specific systemic treatment strategies for those with brain metastases<strong> </strong>from oncogenic driver-mutated NSCLC (<strong>without</strong> severe mass effect or the threat of herniation) are as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>ALK</em></strong> – For patients with <em>ALK</em>-translocated NSCLC, we recommend front-line treatment with a next-generation ALK inhibitor over both <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a> and chemotherapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Appropriate options include <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">alectinib</a>, <a class="drug drug_general" data-topicid="112993" href="/z/d/drug information/112993.html" rel="external">brigatinib</a>, or <a class="drug drug_general" data-topicid="119539" href="/z/d/drug information/119539.html" rel="external">lorlatinib</a>. In the front-line setting, if these agents are unavailable, <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">ceritinib</a> is an acceptable alternative.</p><p></p><p class="bulletIndent2">In the crizotinib-resistant setting, we recommend <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">alectinib</a>, <a class="drug drug_general" data-topicid="119539" href="/z/d/drug information/119539.html" rel="external">lorlatinib</a>, or <a class="drug drug_general" data-topicid="112993" href="/z/d/drug information/112993.html" rel="external">brigatinib</a> over chemotherapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>), but <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">ceritinib</a> is an acceptable alternative  (<a class="graphic graphic_algorithm graphicRef138738" href="/z/d/graphic/138738.html" rel="external">algorithm 3</a>). (See <a class="local">'ALK translocations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>ROS1</em></strong> – For patients with <em>ROS1</em>-mutated tumors, we suggest <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">entrectinib</a> over <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a>  (<a class="graphic graphic_algorithm graphicRef138737" href="/z/d/graphic/138737.html" rel="external">algorithm 2</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'ROS1 translocations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>EGFR</em></strong> – For patients with <em>EGFR</em>-mutated tumors  (<a class="graphic graphic_algorithm graphicRef138727" href="/z/d/graphic/138727.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Who present with brain metastases, we recommend initial treatment with <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> over earlier-generation TKIs or chemotherapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'EGFR mutations'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Who develop both intracranial and extracranial progression on a first- or second-generation EGFR TKI, we obtain biopsy of the most accessible site. For those with a <em>T790M</em> resistance mutation, we recommend <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> over chemotherapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). For those lacking a <em>T790M</em> resistance mutation, we treat with RT followed by systemic chemotherapy, along the lines of treatment for those lacking driver mutations. (See <a class="local">'Brain metastases upon progression on TKI'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Who develop isolated intracranial progression on a first- or second-generation EGFR TKI, we suggest a transition to <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Switching to osimertinib may obviate the need for local therapy and reduce the risk of further CNS progression compared with continuation of the original EGFR TKI. In the setting of limited data, however, one may alternatively use local therapies for the brain metastases and continue the original TKI; or obtain a biopsy, with approach dictated by the results. (See <a class="local">'Brain metastases upon progression on TKI'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>MET</em></strong> – For patients with <em>MET</em> exon-14-skipping mutations, we suggest <a class="drug drug_general" data-topicid="128126" href="/z/d/drug information/128126.html" rel="external">capmatinib</a> rather than chemotherapy or immunotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="130698" href="/z/d/drug information/130698.html" rel="external">Tepotinib</a> is a reasonable alternative. (See <a class="local">'MET exon-14-skipping mutations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>RET</em></strong> – For patients with a <em>RET</em> rearrangement, we suggest the RET inhibitor <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">selpercatinib</a> or <a class="drug drug_general" data-topicid="129470" href="/z/d/drug information/129470.html" rel="external">pralsetinib</a> rather than chemotherapy or immunotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'RET fusions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without targetable oncogenic drivers, lacking surgical indications</strong> – For patients lacking a driver mutation and without indication for neurosurgical management, we suggest RT  (<a class="graphic graphic_algorithm graphicRef138728" href="/z/d/graphic/138728.html" rel="external">algorithm 4</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), although systemic therapy is a reasonable alternative initial management strategy, particularly for those with asymptomatic brain metastases. Additionally, for those with poor performance status, best supportive care may be used instead. (See <a class="local">'Chemotherapy, with or without immunotherapy'</a> above and <a class="local">'Best supportive care'</a> above.)</p><p></p><p class="headingAnchor" id="H103075242"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledges Alice T Shaw, MD, PhD, and Howard (Jack) West, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004; 22:2865.</a></li><li><a class="nounderline abstract_t">Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002; 94:2698.</a></li><li><a class="nounderline abstract_t">Schuette W. Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer 2004; 45 Suppl 2:S253.</a></li><li><a class="nounderline abstract_t">Johung KL, Yeh N, Desai NB, et al. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. J Clin Oncol 2016; 34:123.</a></li><li><a class="nounderline abstract_t">Zhang I, Zaorsky NG, Palmer JD, et al. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol 2015; 16:e510.</a></li><li><a class="nounderline abstract_t">Shin DY, Na II, Kim CH, et al. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol 2014; 9:195.</a></li><li><a class="nounderline abstract_t">Gainor JF, Tseng D, Yoda S, et al. Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer. JCO Precis Oncol 2017; 2017.</a></li><li><a class="nounderline abstract_t">Patil T, Smith DE, Bunn PA, et al. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol 2018; 13:1717.</a></li><li><a class="nounderline abstract_t">Kim JE, Lee DH, Choi Y, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009; 65:351.</a></li><li><a class="nounderline abstract_t">Porta R, Sánchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011; 37:624.</a></li><li><a class="nounderline abstract_t">Jamal-Hanjani M, Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res 2012; 18:938.</a></li><li><a class="nounderline abstract_t">Wu YL, Zhou C, Cheng Y, et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol 2013; 24:993.</a></li><li><a class="nounderline abstract_t">Hochmair M, Holzer S, Burghuber OC. Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases. Anticancer Drugs 2016; 27:914.</a></li><li><a class="nounderline abstract_t">Li D, Zhu X, Wang H, et al. Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis. J Thorac Dis 2017; 9:310.</a></li><li><a class="nounderline abstract_t">Tanvetyanon T, Robinson LA, Schell MJ, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 2008; 26:1142.</a></li><li><a class="nounderline abstract_t">Hu C, Chang EL, Hassenbusch SJ 3rd, et al. Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis. Cancer 2006; 106:1998.</a></li><li><a class="nounderline abstract_t">Hata A, Katakami N, Yoshioka H, et al. Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI. J Thorac Oncol 2015; 10:1553.</a></li><li><a class="nounderline abstract_t">Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol 2022; 40:492.</a></li><li><a class="nounderline abstract_t">Tallet AV, Azria D, Barlesi F, et al. Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol 2012; 7:77.</a></li><li><a class="nounderline abstract_t">Wen PY. Controversies in neuro-oncology: role of whole-brain radiation therapy in the treatment of newly diagnosed brain metastases. Neuro Oncol 2015; 17:915.</a></li><li><a class="nounderline abstract_t">Thomas NJ, Myall NJ, Sun F, et al. Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation. J Thorac Oncol 2022; 17:116.</a></li><li><a class="nounderline abstract_t">Gadgeel SM, Shaw AT, Govindan R, et al. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol 2016; 34:4079.</a></li><li><a class="nounderline abstract_t">Kim DW, Mehra R, Tan DS, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol 2016; 17:452.</a></li><li class="breakAll">Brigatinib tablets, for oral use. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208772s008lbl.pdf (Accessed on May 26, 2020).</li><li class="breakAll">Ceritinib capsules, for oral use. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205755s016lbl.pdf (Accessed on May 26, 2020).</li><li class="breakAll">Lorlatinib tablets. United States Prescribing Information. US National Library of Medicine. http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf (Accessed on June 21, 2019).</li><li><a class="nounderline abstract_t">Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 2017; 390:29.</a></li><li><a class="nounderline abstract_t">Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2017; 377:829.</a></li><li><a class="nounderline abstract_t">Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. J Clin Oncol 2017; 35:2490.</a></li><li><a class="nounderline abstract_t">Camidge R, Kim HR, Ahn MJ, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial. Ann Oncol 2019; 30S: ESMO Asia #LBA1.</a></li><li><a class="nounderline abstract_t">Soria JC, Tan DS, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 2017; 389:917.</a></li><li><a class="nounderline abstract_t">Chow LQ, Barlesi F, Bertino EM, et al. Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain. Ann Oncol 2019; 30S: ESMO #1478O.</a></li><li><a class="nounderline abstract_t">Gainor JF, Sherman CA, Willoughby K, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 2015; 10:232.</a></li><li><a class="nounderline abstract_t">Shaw AT, Bauer TM, de Marinis F, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med 2020; 383:2018.</a></li><li><a class="nounderline abstract_t">Solomon BJ, Bauer TM, Ignatius Ou SH, et al. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study. J Clin Oncol 2022; 40:3593.</a></li><li class="breakAll">Alectinib capsules, for oral use. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf (Accessed on May 26, 2020).</li><li><a class="nounderline abstract_t">Novello S, Mazières J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol 2018; 29:1409.</a></li><li><a class="nounderline abstract_t">Lin JJ, Jiang GY, Joshipura N, et al. Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases. J Thorac Oncol 2019; 14:683.</a></li><li><a class="nounderline abstract_t">Camidge DR, Kim DW, Tiseo M, et al. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. J Clin Oncol 2018; 36:2693.</a></li><li><a class="nounderline abstract_t">Gettinger SN, Bazhenova LA, Langer CJ, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol 2016; 17:1683.</a></li><li><a class="nounderline abstract_t">Huber RM, Hansen KH, Paz-Ares Rodríguez L, et al. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. J Thorac Oncol 2020; 15:404.</a></li><li><a class="nounderline abstract_t">Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol 2017; 18:1590.</a></li><li><a class="nounderline abstract_t">Dagogo-Jack I, Oxnard GR, Evangelist M, et al. Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse. JCO Precis Oncol 2022; 6:e2100522.</a></li><li><a class="nounderline abstract_t">Solomon B, Shaw A, Ou S, et al. Phase 2 study of lorlatinib in patients with advanced ALK+/ROS1+ non-small-cell lung cancer. J Thorac Oncol 2017; 12S: WCLC #OA 05.06.</a></li><li><a class="nounderline abstract_t">Crinò L, Ahn MJ, De Marinis F, et al. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. J Clin Oncol 2016; 34:2866.</a></li><li><a class="nounderline abstract_t">Chow LQM, Barlesi F, Bertino EM, et al. ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. Clin Cancer Res 2022; 28:2506.</a></li><li><a class="nounderline abstract_t">Horn L, Infante JR, Reckamp KL, et al. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clin Cancer Res 2018; 24:2771.</a></li><li><a class="nounderline abstract_t">Gainor JF, Chi AS, Logan J, et al. Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib. J Thorac Oncol 2016; 11:256.</a></li><li><a class="nounderline abstract_t">Iuchi T, Shingyoji M, Sakaida T, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 2013; 82:282.</a></li><li><a class="nounderline abstract_t">Grommes C, Oxnard GR, Kris MG, et al. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011; 13:1364.</a></li><li><a class="nounderline abstract_t">Gerber NK, Yamada Y, Rimner A, et al. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. Int J Radiat Oncol Biol Phys 2014; 89:322.</a></li><li><a class="nounderline abstract_t">Magnuson WJ, Yeung JT, Guillod PD, et al. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases. Int J Radiat Oncol Biol Phys 2016; 95:673.</a></li><li><a class="nounderline abstract_t">Magnuson WJ, Lester-Coll NH, Wu AJ, et al. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. J Clin Oncol 2017; 35:1070.</a></li><li><a class="nounderline abstract_t">Soon YY, Leong CN, Koh WY, Tham IW. EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis. Radiother Oncol 2015; 114:167.</a></li><li><a class="nounderline abstract_t">Welsh JW, Komaki R, Amini A, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 2013; 31:895.</a></li><li><a class="nounderline abstract_t">Sperduto PW, Wang M, Robins HI, et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 2013; 85:1312.</a></li><li><a class="nounderline abstract_t">Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378:113.</a></li><li><a class="nounderline abstract_t">Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2018; :JCO2018783118.</a></li><li><a class="nounderline abstract_t">Chiu CH, Tsai CM, Chen YM, et al. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 2005; 47:129.</a></li><li><a class="nounderline abstract_t">Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004; 15:1042.</a></li><li><a class="nounderline abstract_t">Wu C, Li YL, Wang ZM, et al. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 2007; 57:359.</a></li><li><a class="nounderline abstract_t">Zee YK, Chin TM, Wong AS. Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer. J Clin Oncol 2009; 27:e145.</a></li><li><a class="nounderline abstract_t">Zhou L, He J, Xiong W, et al. Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study. Lung Cancer 2016; 96:93.</a></li><li><a class="nounderline abstract_t">Zeng YD, Liao H, Qin T, et al. Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. Oncotarget 2015; 6:8366.</a></li><li><a class="nounderline abstract_t">Deng Y, Feng W, Wu J, et al. The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. Mol Clin Oncol 2014; 2:116.</a></li><li><a class="nounderline abstract_t">Togashi Y, Masago K, Fukudo M, et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol 2010; 5:950.</a></li><li><a class="nounderline abstract_t">Tamiya A, Tamiya M, Nishihara T, et al. Efficacy and cerebrospinal fluid concentration of afatinib in NSCLC patients with EGFR mutations developing leptomeningeal carcinomatosis. J Thorac Oncol 2016; 12S: WCLC #OA08.05.</a></li><li><a class="nounderline abstract_t">Ballard P, Yates JW, Yang Z, et al. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res 2016; 22:5130.</a></li><li><a class="nounderline abstract_t">Nanjo S, Hata A, Okuda C, et al. Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer. Br J Cancer 2018; 118:32.</a></li><li><a class="nounderline abstract_t">Yang JCH, Kim SW, Kim DW, et al. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. J Clin Oncol 2020; 38:538.</a></li><li><a class="nounderline abstract_t">Clarke JL, Pao W, Wu N, et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010; 99:283.</a></li><li><a class="nounderline abstract_t">Baik CS, Chamberlain MC, Chow LQ. Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer. J Thorac Oncol 2015; 10:1268.</a></li><li><a class="nounderline abstract_t">McGranahan T, Nagpal S. A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer. Curr Treat Options Oncol 2017; 18:22.</a></li><li><a class="nounderline abstract_t">Schuler M, Wu YL, Hirsh V, et al. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. J Thorac Oncol 2016; 11:380.</a></li><li><a class="nounderline abstract_t">Mok T, Myung-Ju A, Han Ji-Youn, et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3). J Clin Oncol 2017; 35S: ASCO #9005.</a></li><li><a class="nounderline abstract_t">Wu YL, Ahn MJ, Garassino MC, et al. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol 2018; 36:2702.</a></li><li><a class="nounderline abstract_t">Park W, Mudad R. Central nervous system (CNS) responses to osimertinib in brain metastases in brain metastases from lung cancer (NSCLC) with T790M: Effectiveness of the 80 mg dose. J Thorac Oncol 2017; 12S: WCLC #P3.02b.</a></li><li><a class="nounderline abstract_t">Koba T, Kijima T, Takimoto T, et al. Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports. Medicine (Baltimore) 2017; 96:e6087.</a></li><li><a class="nounderline abstract_t">Park S, Lee MH, Seong M, et al. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Ann Oncol 2020; 31:1397.</a></li><li><a class="nounderline abstract_t">Wu YL, Yang JC, Kim DW, et al. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2018; 36:1405.</a></li><li><a class="nounderline abstract_t">Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020; 21:261.</a></li><li><a class="nounderline abstract_t">Dziadziuszko R, Krebs MG, De Braud F, et al. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol 2021; 39:1253.</a></li><li class="breakAll">Entrectinib capsules. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf (Accessed on September 13, 2019).</li><li><a class="nounderline abstract_t">Lim SM, Kim HR, Lee JS, et al. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. J Clin Oncol 2017; 35:2613.</a></li><li><a class="nounderline abstract_t">Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol 2019; 20:1691.</a></li><li><a class="nounderline abstract_t">Cho BCC, Drilon AE, Doebele RC, et al. Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study). J Clin Oncol 2019; 37S: ASCO #9011.</a></li><li class="breakAll">Capmatinib tablets. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf (Accessed on May 07, 2020).</li><li class="breakAll">Tepotinib tablets. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf (Accessed on March 05, 2021).</li><li><a class="nounderline abstract_t">Paik PK, Felip E, Veillon R, et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med 2020; 383:931.</a></li><li><a class="nounderline abstract_t">Garon EB, Heist RS, Seto T, et al. Capmatinib in METex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRY mono-1 study, including efficacy in patients (pts) with brain metastases (BM). Cancer Res 2020; 80S: AACR #CT082.</a></li><li class="breakAll">Selpercatinib capsules. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf (Accessed on May 11, 2020).</li><li class="breakAll">Pralsetinib capsules. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf (Accessed on March 05, 2021).</li><li><a class="nounderline abstract_t">Zhou C, Solomon B, Loong HH, et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med 2023; 389:1839.</a></li><li><a class="nounderline abstract_t">Subbiah V, Gainor JF, Oxnard GR, et al. Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. Clin Cancer Res 2021; 27:4160.</a></li><li><a class="nounderline abstract_t">Drilon A, Subbiah V, Gautschi O, et al. Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. J Clin Oncol 2023; 41:385.</a></li><li><a class="nounderline abstract_t">Gainor JF, Lee DH, Curigliano G, et al. Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-fusion+ non-small cell lung cancer. J Clin Oncol 2019; 37S: ASCO #9008.</a></li><li><a class="nounderline abstract_t">Negrao MV, Spira AI, Heist RS, et al. Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases. J Clin Oncol 2023; 41:4472.</a></li><li><a class="nounderline abstract_t">Ramalingam S, Skoulidis R, Govinan R, et al. P52.03 Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100. J Thorac Oncol 2021; 16(10): S1123.</a></li><li><a class="nounderline abstract_t">Olmez I, Donahue BR, Butler JS, et al. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis. Lung Cancer 2010; 70:174.</a></li><li><a class="nounderline abstract_t">Nadal E, Rodríguez-Abreu D, Simó M, et al. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05). J Clin Oncol 2023; 41:4478.</a></li><li><a class="nounderline abstract_t">Lee DH, Han JY, Kim HT, et al. Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first : result of a randomized pilot study. Cancer 2008; 113:143.</a></li><li><a class="nounderline abstract_t">Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999; 85:1599.</a></li><li><a class="nounderline abstract_t">Fujita A, Fukuoka S, Takabatake H, et al. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology 2000; 59:291.</a></li><li><a class="nounderline abstract_t">Cortes J, Rodriguez J, Aramendia JM, et al. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology 2003; 64:28.</a></li><li><a class="nounderline abstract_t">Bailon O, Chouahnia K, Augier A, et al. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. Neuro Oncol 2012; 14:491.</a></li><li><a class="nounderline abstract_t">Bearz A, Garassino I, Tiseo M, et al. Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. Lung Cancer 2010; 68:264.</a></li><li><a class="nounderline abstract_t">Wong ET, Berkenblit A. The role of topotecan in the treatment of brain metastases. Oncologist 2004; 9:68.</a></li><li><a class="nounderline abstract_t">Dziadziuszko R, Ardizzoni A, Postmus PE, et al. Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 2003; 39:1271.</a></li><li><a class="nounderline abstract_t">Siena S, Crinò L, Danova M, et al. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol 2010; 21:655.</a></li><li><a class="nounderline abstract_t">Ebert BL, Niemierko E, Shaffer K, Salgia R. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist 2003; 8:69.</a></li><li><a class="nounderline abstract_t">Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001; 53:259.</a></li><li><a class="nounderline abstract_t">Christodoulou C, Bafaloukos D, Kosmidis P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001; 12:249.</a></li><li><a class="nounderline abstract_t">Giorgio CG, Giuffrida D, Pappalardo A, et al. Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. Lung Cancer 2005; 50:247.</a></li><li><a class="nounderline abstract_t">Hubbeling HG, Schapira EF, Horick NK, et al. Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer. J Thorac Oncol 2018; 13:550.</a></li><li><a class="nounderline abstract_t">Shepard MJ, Xu Z, Donahue J, et al. Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study. J Neurosurg 2019; :1.</a></li><li><a class="nounderline abstract_t">Scoccianti S, Olmetto E, Pinzi V, et al. Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO. Neuro Oncol 2021; 23:1750.</a></li><li><a class="nounderline abstract_t">Hendriks LEL, Henon C, Auclin E, et al. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. J Thorac Oncol 2019; 14:1244.</a></li><li><a class="nounderline abstract_t">Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 2016; 17:976.</a></li><li><a class="nounderline abstract_t">Goldberg SB, Schalper KA, Gettinger SN, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol 2020; 21:655.</a></li><li><a class="nounderline abstract_t">Crinò L, Bronte G, Bidoli P, et al. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer 2019; 129:35.</a></li><li><a class="nounderline abstract_t">Bidoli P, Chiari R, Catino A, et al. Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Acess Programme (EAP) in Italy. Ann Oncol 2016; 27S: ESMO #1228P.</a></li><li><a class="nounderline abstract_t">Dudnik E, Yust-Katz S, Nechushtan H, et al. Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer 2016; 98:114.</a></li><li><a class="nounderline abstract_t">Lukas RV, Gandhi M, et al, O'Hear C. Safety and efficacy analyses of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients with or without baseline brain metastases. Ann Oncol 2017; 28S: ELCC #81O.</a></li><li><a class="nounderline abstract_t">Ali A, Goffin JR, Arnold A, Ellis PM. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol 2013; 20:e300.</a></li><li><a class="nounderline abstract_t">Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet 2016; 388:2004.</a></li><li><a class="nounderline abstract_t">Bauer TM, Shaw AT, Johnson ML, et al. Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. Target Oncol 2020; 15:55.</a></li><li><a class="nounderline abstract_t">Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014; 15:1119.</a></li><li><a class="nounderline abstract_t">Guo R, Schreyer M, Chang JC, et al. Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases. JCO Precis Oncol 2019; 3.</a></li><li><a class="nounderline abstract_t">Lee J, Choi Y, Han J, et al. Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status. J Thorac Oncol 2020; 15:1758.</a></li></ol></div><div id="topicVersionRevision">Topic 114697 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15254054" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12173339" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15552807" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment of brain metastases from lung cancer: chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26438117" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26433824" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24419416" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : EGFR mutation and brain metastasis in pulmonary adenocarcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29333528" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29981925" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19157632" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20595147" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22167408" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23129122" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27442131" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28275479" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18309950" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16572401" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26309190" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34932393" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22640600" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26092876" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Controversies in neuro-oncology: role of whole-brain radiation therapy in the treatment of newly diagnosed brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34455066" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27863201" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26973324" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26973324" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26973324" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26973324" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28501140" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28586279" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28475456" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28126333" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25526238" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33207094" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35605188" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35605188" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29668860" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30529198" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29768119" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27836716" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31756496" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29074098" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35584349" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Phase 2 study of lorlatinib in patients with advanced ALK+/ROS1+ non-small-cell lung cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27432917" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35091443" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29563138" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26845119" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24021541" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21865399" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24679729" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27034176" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28113019" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25583566" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23341526" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23391814" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29151359" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30153097" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15603863" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15205197" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17434236" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19667265" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27133757" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25788260" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24649318" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20479691" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Efficacy and cerebrospinal fluid concentration of afatinib in NSCLC patients with EGFR mutations developing leptomeningeal carcinomatosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27435396" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29190637" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31809241" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20146086" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26107553" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28391420" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26823294" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30059262" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Central nervous system (CNS) responses to osimertinib in brain metastases in brain metastases from lung cancer (NSCLC) with T790M: Effectiveness of the 80 mg dose</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28178168" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32634610" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29596029" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31838015" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33646820" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33646820" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28520527" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31669155" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32469185" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Capmatinib in METex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRY mono-1 study, including efficacy in patients (pts) with brain metastases (BM)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Capmatinib in METex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRY mono-1 study, including efficacy in patients (pts) with brain metastases (BM)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Capmatinib in METex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRY mono-1 study, including efficacy in patients (pts) with brain metastases (BM)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870973" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34088726" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36122315" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-fusion+ non-small cell lung cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37327468" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : P52.03 Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20207442" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37603816" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18459180" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first : result of a randomized pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10193952" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11096340" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12457029" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22362813" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19632738" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14755016" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The role of topotecan in the treatment of brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12763216" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19767314" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12604733" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11718258" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11300333" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16039010" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29378267" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31349225" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34050669" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30780002" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27267608" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32251621" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30797489" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Acess Programme (EAP) in Italy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27393516" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Safety and efficacy analyses of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients with or without baseline brain metastases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23904768" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27604504" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32060867" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25153538" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31485557" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32652216" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
